The FDA announced that Ozempic and Wegovy supply problems had ended and set final deadlines for pharmacies to stop making compounded semaglutide: Individual pharmacy locations: Required to stop by April 22, 2025 Commercial compounding operations: Discontinue production by May 22, 2025 So, compounded semaglutide was not available after May 22, 2025, except in exceptional medical circumstances where standard formulations are ineffective
Interaction between gut microbiome and cardiovascular disease
Researchers exploring why not losing weight on semaglutide or similar challenges should consider that weight loss plateaus are common after six to nine months and may require dose adjustments or lifestyle modifications
With Kardashians influence and a focus on natural weight management, many are wondering: is this the real deal, or just another wellness trend wrapped in fancy packaging
These medications have MHRA restrictions and should be used at the lowest effective dose for the shortest duration under medical supervision
Good science is good business: AG1 and IIFH partnership to advance metabolic health The Innovation Institute for Food and Health (IIFH) at UC Davis partnered with AG1 to accelerate product development for nutrition and metabolic health innovations and commercialize research discoveries